Histomorphological Study of a New Nasal Spray with Anti-inflammatory Properties Efficacy in Rabbits with Rhinosinusitis

Зупанец, И. А.; Zhulai, T. S.; Shebeko, S. K.; Отришко, И. А.; Hladkykh, Dmytro

doi:10.5455/medarh.2020.74.8-13

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, 56.9% of the total number of respondents were obese (BMI> 25 kg/m 2 ). There were statistically significantly more obese respondents with unregulated HbA1c values>7.1% compared to obese respondents with HbA1c<7.0% (34.9%) and only in the case of retinopathy it was shown that of the total number of respondents with BMI>25 kg/m 2 , 41.8% of them have this microvascular complication, which is in line with the results of other scientific studies showing that obesity and poor glycemic control are significant risk factors for microvascular complications including diabetic foot ulcer ( 21 - 23 ).…”

Section: Discussionsupporting

confidence: 88%

Correlation Between Extracutaneous Microvascular Complications and Diabetic Foot Ulcers in Patients with Type 2 Diabetes Mellitus

Balaban

Bijelic²,

Miličević

et al. 2020

Med Arch

View full text Add to dashboard Cite

Background: Diabetes is a metabolic disease that is taking an epidemic proportion around the world. The occurrence of microvascular complications and diabetic foot ulcer is associated with an increased mortality and morbidity incidence, which is the most serious complication of this disease, which significantly reduce the quality of patient life. Objective. The aim of the study was to determine the correlation of extracutaneous microvascular complications with diabetic foot ulcer in patients with type 2 diabetes. Method. The study was prospective, and included 160 patients with type 2 diabetes. It was conducted at the University Clinical Center of the Republic of Srpska in the period from January 2016 until December 2019. The respondents were adults, of both sexes, suffering from type 2 diabetes, in whom complications of this disease are present. Glycemic control was established based on a target HbA1c value of 7%. Results. Of the 160 patients in the study, 53.8% were men and 46.2% were women. The average age of the patients was 70.11%±10.05 years. Extracutaneous microvascular complications were present in 85 patients (53.1%); of which 30.2% had well-regulated glycemia (HbA1c≤7.0%), while 61.5% (p<0.001) had unregulated glycemia (HbA1c≥7.0). Polyneuropathy was present in 23.3% of patients with HbA1c≤7.0%, while 41.0% of patients had HbA1c≥7.0% (p<0.043). Nephropathy with HbA1c≤7.0% was present in 36.8% of cases compared to patients with HbA1c≥7.0 in whom the prevalence was 36.8% (p<0.004). Out of total, 25.6% had retinopathy with HbA1c≤7.0%, while in 41.9% of patients with HbA1c≥7.0% (p <0.067). Diabetic ulcer foot was present in 13 patients with HbA1c≥7 (11.1%) compared to patients with HbA1c≤7.0% where there was no occurrence of this complication 0.0% (p<0.021). At the same time, 5.6% of patients had a diabetic foot ulcer with polyneuropathy (p=0.010), 4.4% had neuropathy (p=0.058) and 5.6% had retinopathy (p=0.014). Conclusion: The high incidence of extracutaneous microvascular complications and diabetic foot ulcer in patients with type 2 diabetes requires a multidisciplinary approach of medical professionals that includes prevention of risk factors and good regulation of glycemia.

show abstract

Section: Discussionsupporting

confidence: 88%

Correlation Between Extracutaneous Microvascular Complications and Diabetic Foot Ulcers in Patients with Type 2 Diabetes Mellitus

Balaban

Bijelic²,

Miličević

et al. 2020

Med Arch

View full text Add to dashboard Cite

show abstract

“…Гистоморфологическое исследование выявило значительное уменьшение признаков воспаления в эпителии носовых полостей и слизистой оболочки придаточных пазух носа. Эффективность энисамия йодида не уступала препарату сравнения синупрет ® в таблетках, скорость начала действия была выше таковой для синупрета [86]. Топическое применение энисамия йодида в модели зимозанового воспаления стопы у крыс обнаружило высокую скорость наступления антиэкссудативного эффекта, выраженность противовоспалительного действия на 30-й минуте превосходила ибупрофен в 1,5 раза, остальное время была сопоставима, что позволило авторам сделать вывод о возможном потенциале энисамия йодида для ингибирования липооксигеназного пути метаболизма арахидоновой кислоты [87].…”

Section: энисамия йодидunclassified

Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities

Zyryanov

Бутранова

Гайдай³

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Routinely the influenza virus significantly contributes to the formation of the annual incidence of acute respiratory infections, with a peak in winter season. The high level of mutagenic potential of influenza viruses is a standard factor determining the complexity of the rational choice of pharmacotherapy. The upcoming epidemiological season 20202021 brings additional challenges for health care practitioners mediated by the widespread prevalence in the human population of a new infection caused by the SARS-CoV-2 virus affecting the respiratory system among many organs and systems. An adequate choice of pharmacotherapy tools should be based on high efficiency and safety of drugs, with a possible reduction in such negative factors as polypharmacy. This review includes comparative pharmacological characteristics of drugs with activity against RNA viruses, along with parameters of their clinical efficacy.

show abstract

“…Противовоспалительная эффективность энисамия йодида в форме назального спрея (10 мг/мл) также была показана в экспериментах in vivo на животных, на модели экспериментального риносинусита у кроликов. Гистоморфологическое исследование выявило значительное уменьшение признаков воспаления в эпителии носовых полостей и слизистой оболочки придаточных пазух носа кроликов в результате применения энисамия йодида [6]. Поэтому можно полагать, что препарат демонстрирует эффективность не только при системном применении, но и при местном, для которого не требуется образование метаболитов.…”

Section: Introductionunclassified

The mechanisms of anti-inflammatory action of enisamium iodide

Федотчева

Semeikin

et al. 2022

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. The role of cyclooxygenases (COX-1 and/or COX-2), transcription nuclear factor NF-B, anti-inflammatory cytokines TGF1b, IL-4, IL-10 and pro-inflammatory cytokines IL-1, IL-6 were studied to substantiate the expediency of antiviral agent enisamium iodide (Nobazit) using to regulate key inflammatory components in acute respiratory infections, IL-8, TNF-alpha in the realization of the pharmacological activity of this drug. Materials and methods. Gene expression was determined by real-time RT-PCR, the concentration of interleukins was determined by ELISA, and the viability of peripheral blood mononuclear cells (PBMC) was assessed by the MTT spectrophotometric method. The chemiluminescence method was used to assess PBMC oxidant activity. Results. Enisamium iodide (10 M) reduced mRNA levels of COX-1, COX-2, NF-B, TGF1b, IL-1, IL-6 in stimulated PBMC of healthy donors by an average of 48% (p0.05). At 5 times higher concentration, 50 M, enisamium iodide suppressed the expression of these genes by an average of 43% (p0.05). At a concentration of 100 M, enisamium iodide reduced the expression of COX-2, TGF1b, IL-1, IL-6 by an average of 47% (p0.05). At a concentration of 10 M, enisamium iodide stimulated the secretion of IL-10 by mononuclear cells by 1.2 times, p0.05. The tested drug at a concentration of 50 M did not affected on the concentration of IL-1, IL-4, IL-8 and TNF-alpha, but significantly stimulated the production of IL-10 by 1.5 times, p0.05. The chemiluminescence method revealed that enisamium iodide in the entire concentration range (10100 M) does not reduce the viability of macrophages, but inhibits their oxidative activity (maximum value of CL intensity) by an average of 55% (p0.05). Conclusion. The anti-inflammatory effect of enisamium iodide at a concentration of 10 M may be associated with inhibition of the expression of COX-1, 2, NF-B, IL-1, IL-6, TGF1b and an increase in the expression and production of IL-10. An additional contribution to the anti-inflammatory activity of enisamium iodide is made by its antioxidant and antiradical activity. The absence of the effect of enisamium iodide (10100 M) on the viability of PBMC indicates its safety for the cells of the immune system and the expediency of using it to suppress inflammatory reactions in acute respiratory infections, restore the quality of life of patients and the possibility of using Nobazit as an effective agent for treatment of these infections of various etiologies.

show abstract

Histomorphological Study of a New Nasal Spray with Anti-inflammatory Properties Efficacy in Rabbits with Rhinosinusitis

Cited by 3 publications

References 12 publications

Correlation Between Extracutaneous Microvascular Complications and Diabetic Foot Ulcers in Patients with Type 2 Diabetes Mellitus

Correlation Between Extracutaneous Microvascular Complications and Diabetic Foot Ulcers in Patients with Type 2 Diabetes Mellitus

Pharmacotherapy for acute respiratory infections caused by influenza viruses: current possibilities

The mechanisms of anti-inflammatory action of enisamium iodide

Contact Info

Product

Resources

About